End-Stage Kidney Disease - Pipeline Review, H1 2017
End-Stage Kidney Disease - Pipeline Review, H1 2017
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease - Pipeline Review, H1 2017, provides an overview of the End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.
End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide End-Stage Kidney Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1 and 2 respectively.
End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease - Pipeline Review, H1 2017, provides an overview of the End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.
End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide End-Stage Kidney Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1 and 2 respectively.
End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development
BLR Bio LLC
CTI BioPharma Corp
F. Hoffmann-La Roche Ltd
Novartis AG
Prolong Pharmaceuticals LLC
VESSL Therapeutics Ltd
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles
BLR-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
calcium succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MultiGeneGraft - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obinutuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pacritinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sanguinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tesidolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development
BLR Bio LLC
CTI BioPharma Corp
F. Hoffmann-La Roche Ltd
Novartis AG
Prolong Pharmaceuticals LLC
VESSL Therapeutics Ltd
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles
BLR-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
calcium succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MultiGeneGraft - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obinutuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pacritinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sanguinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tesidolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BLR Bio LLC, H1 2017
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by CTI BioPharma Corp, H1 2017
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Novartis AG, H1 2017
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Prolong Pharmaceuticals LLC, H1 2017
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by VESSL Therapeutics Ltd, H1 2017
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, H1 2017
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products, H1 2017
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BLR Bio LLC, H1 2017
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by CTI BioPharma Corp, H1 2017
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Novartis AG, H1 2017
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Prolong Pharmaceuticals LLC, H1 2017
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by VESSL Therapeutics Ltd, H1 2017
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, H1 2017
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products, H1 2017
LIST OF FIGURES
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
COMPANIES MENTIONED
BLR Bio LLC
CTI BioPharma Corp
F. Hoffmann-La Roche Ltd
Novartis AG
Prolong Pharmaceuticals LLC
VESSL Therapeutics Ltd
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
COMPANIES MENTIONED
BLR Bio LLC
CTI BioPharma Corp
F. Hoffmann-La Roche Ltd
Novartis AG
Prolong Pharmaceuticals LLC
VESSL Therapeutics Ltd
